PDA Technical Report 82 has become a . The Parenteral Drug Association—founded in 1946 as a non-profit organization dedicated to advancing pharmaceutical and biopharmaceutical science and regulation—publishes technical reports that are highly valued as essential references by industry and regulatory authorities globally. PDA TR 82 is explicitly used as guidance for performing LER studies for BLA submissions to the FDA's Center for Drug Evaluation and Research (CDER).
It is crucial to note that PDA TR 82 is not a regulatory standard or a compendial chapter (like USP). It is a technical report —a best-practices guideline. However, regulators expect manufacturers to be aware of its contents and justify any deviation from its recommendations.
[Characterize Product & Packaging] ➔ Define Tg, freezing kinetics, and CCI limits. ▼ [Select & Qualify Equipment] ➔ Conduct extreme-low temperature mapping and hold studies. ▼ [Establish Operational Controls] ➔ Implement CMS, TOE limits, and safety infrastructure. ▼ [Validate Logistics & Lifecycles] ➔ Create robust disaster recovery and transfer protocols.
Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA. pda technical report 82
[Spiked Endotoxin] ──► Incubated in Product Matrix ──► Aggregates Dissociate ──► Monomers Masked ──►
: LER studies should be performed on three product batches and conducted under process-relevant conditions.
The PDA has opened a peer reviewer volunteer opportunity for the revision of TR 82 (Low Endotoxin Recovery), inviting subject matter experts to contribute their expertise to the updated document. PDA Technical Report 82 has become a
However, older facilities or systems with design limitations (e.g., pump cavitation issues at low flow, dead legs, or undersized pumps) may not be able to achieve or sustain these high flow rates during thermal treatment. Historically, regulators viewed low-flow sanitization with skepticism due to concerns about "cold spots" where bacteria could survive.
) and the rigorous demands of deep-freeze environments. The report specifically focuses on temperatures ranging from -20∘Cnegative 20 raised to the composed with power C down to cryogenic states below -150∘Cnegative 150 raised to the composed with power C Key Objectives
: The debate between RSE/CSE versus NOEs will likely receive further attention, as the current version specifies the use of CSE or RSE as preferred standards It is crucial to note that PDA TR
The official scope of PDA TR 82 is to address the Low Endotoxin Recovery (LER) phenomenon. According to the report's summary, it has four primary aims:
Low Endotoxin Recovery (LER) is a time- and temperature-dependent phenomenon where a known amount of bacterial endotoxin becomes undetectable over time when spiked into an undiluted drug product. First reported publicly by Chen and Vinther in 2013, LER specifically affects biologics and monoclonal antibodies. The Criteria for LER
: Early sections of TR 82 address the history of LER studies, define key terms that have been used interchangeably in the past, and propose the underlying mechanisms driving endotoxin masking.
Parenteral drug products, which include injections and infusions, are critical for the treatment of various medical conditions, including chronic diseases, infections, and cancers. Due to their direct administration into the body, parenteral products pose significant risks to patients if they are not manufactured and controlled properly. The PDA Technical Report 82 aims to provide a comprehensive framework for ensuring the quality, safety, and efficacy of parenteral drug products.
PDA Technical Report 82 (TR 82), published in 2019, provides a standardized framework for investigating and mitigating Low Endotoxin Recovery (LER), a phenomenon affecting biological products containing chelating agents and detergents. It outlines procedures for hold-time studies using Reference Standard Endotoxin (RSE) or Control Standard Endotoxin (CSE) to ensure accurate detection and safety. For more details, visit Microcoat . Technical Report No. 82 "Low Endotoxin Recovery"